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Abstract 
Novel Mechanisms of Antigen processing that enhance BCG vaccine efficacy  
Publication No------------------ 
Christopher Raman Singh. B.A., M.S. 
Supervisory Professor: Chinnaswamy Jagannath. Ph.D. 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is the most lethal single 
infectious agent afflicting man today causing 2 million deaths per year.  The World Health 
Organization recommends a vaccine as the best option to prevent this disease.  The current 
vaccine, BCG, has a variable efficacy and does not protect adults.  It is known that BCG 
vaccine becomes sequestered in special phagosome compartments of macrophages that do 
not fuse with lysosomes. Since lysosome fusion is necessary for peptide production and T 
cell priming leading to protective TH1 immunity, we hypothesized that vaccine efficacy is 
reduced and occurs perhaps due to non-lysosome dependent mechanisms. We therefore 
proposed an in depth analysis of phagosome environment, and its proteome to unravel 
mechanisms of antigen processing and presentation. We initially discovered that three 
mechanisms of pH regulation including vacuolar proton ATPase, phagocyte oxidase and 
superoxide dismutase (SOD) secretion from BCG vaccine affect antigen processing within 
phagosomes. These studies led to the discovery that a mutant of BCG vaccine which lacked 
SOD was a better vaccine.  Subsequently, the proteomic analysis of vaccine phagosomes led 
to the discovery of novel protease (γ-secretase) enriched on BCG vaccine phagosomes. We 
then demonstrated that these proteases generated a peptide from the BCG vaccine which was 
presented through the MHC-II pathway to T cells and induced a TH1 response. The 
specificity of antigen production from γ-secretase was confirmed through siRNA 
knockdown of the components of the protease namely, nicastrin, presenilin and APH, which 
led to a decrease in antigen presentation. We therefore conclude that, even though BCG 
phagosomes are sequestered and do not fuse with lysosomes to generate peptide antigens, 
there are complex and novel in situ mechanisms within phagosomes that are capable of 
generating an immune response. We conclude that TH1 immunity to BCG vaccine arises 
mostly due to non-lysosome dependent immune mechanisms of macrophages and dendritic 
cells.  
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INTRODUCTION 
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Tuberculosis 
Tuberculosis (Tb) is the leading cause of death in man due to a single infectious agent and is 
also the number one killer of people co-infected with Human Immunodeficiency Virus 
(HIV-1)(1-3).  The infection can occur in multiple organs but the most common location of 
infection is in the lungs, resulting in pulmonary tuberculosis(4-6).  Tuberculosis symptoms 
include  chronic cough, blood in the sputum, fever and weight loss (6).  Tuberculosis is 
spread when an infected individual with an active form of the disease coughs.  Aerosolizing 
the bacteria and spreading it in the air, and droplets are summarily inhaled by other 
individuals(6).  The majority of people infected are quickly able to contain the infection 
within granulomas in lungs. However, approximately five percent of patients develop acute 
tuberculosis(6).  In many individuals, the infection remains in a latent state until the 
individual becomes immune-compromised, and the infection can take advantage of the 
person’s compromised state.  New threats continue to emerge with this disease, including 
the rise of multi-drug resistant (MDR) infections as well as extensively drug resistant (XDR) 
infections(7-9).  
 
Mycobacterium tuberculosis 
Mycobacterium tuberculosis (M.tuberculosis; Mtb) is the causative agent for tuberculosis.  
The genus Mycobacterium was first observed in 1896 by Lehmann and Neumann(10).  
Mycobacterial members are bacillary shaped organisms.  Mycobacteria are approximately 
3µm long, gram-positive and stain acid fast.  There are three major groups of antigens 
expressed by mycobacteria, cytoplasmic soluble antigens, secreted antigens and cell-wall 
lipid-bound insoluble antigens(10), mycobacteria contain large amounts of surface and 
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soluble lipids and proteins.  Mycobacteria are responsible for two of the most serious 
diseases that plague man, tuberculosis and leprosy (Hansen’s disease).  Mycobacterium 
tuberculosis was first observed and named by Robert Koch in 1882. Currently, 
approximately one-third of the world’s population is latently infected with M.tuberculosis, 
with a new infection occurring about every second. 
 
TREATMENT AND VACCINATION  
There are several options for treatment of tuberculosis, which include the use of  first line 
drugs such as rifampin, pyrazinamide and isoniazid(11-13).  While these drugs are 
bactericidal and can treat the infection, they also cause severe liver toxicity in patients.  
They are less effective in treatment of MDR or XDR strains of infections, leading to the 
alternate use of secondary drugs.  To prevent individuals from contracting tuberculosis, a 
vaccine Bacille Calmette Guerin (BCG) is used, which is derived from Mycobacterium 
bovis. BCG, is a live attenuated vaccine that has been in use since 1921(14-19).  It is one of 
the safest and most distributed vaccines available, with over one billion doses administered 
to date.  There are over thirteen different strains of BCG available for vaccination, although 
efficacy of the vaccination varies from zero to eighty percent, with a higher efficacy for 
protection against childhood pulmonary tuberculosis, but lower efficacy against adult onset 
tuberculosis.  This lack of long term immunity is likely due to the fact that BCG undergoes 
phagosome maturation arrest that prevents the induction of strong, robust and sustained 
immune response(14-19).  The World Health Organization (WHO) has determined that the 
best and most cost effective way to quell this disease is with a novel more effective vaccine. 
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DENDRITIC CELLS AND MACROPHAGES  
Dendritic cells and macrophages are the major antigen presenting cells of the immune 
system.  They phagocytose invading organisms, break them down and load peptide 
fragments onto either MHC class II for presentation to CD4+ T cells, or MHC class I for 
presentation to CD8+ T cells(20).  These are important steps in clearing infection since T 
cells are capable of feed-back activation of macrophages and DCs through cytokines, 
enhance oxidant responses, kill pathogens, help their degradation and enhance immune 
responses, through amplifying peptide production (21,22).  A simple difference between 
macrophages and DCs is that the latter are capable of priming naïve T cells, a process 
whereby a T cell that has never contacted an antigen will become ‘sensitized’ and acquire 
the ability to respond to a repeat dose of antigen, when exposed to the same antigen (23-26).  
Such T cells can also mature into memory T cells when infection is controlled, and then 
undergo recall expansion upon re-infection. Macrophages are generally not capable of 
priming naïve T cells although they can induce expansion of pre-sensitized T cells. Thus, 
DCs are required for the initial priming phase of infection and macrophages for maintenance 
of T cell memory. However, this line is blurred since DCs can continuously sample fresh 
antigens during infection and expand the ‘repertoire’ of T cells. Thus, effective vaccination 
efforts lead to expansion of the activity of both DCs and macrophages. 
      
GENERATION OF AN IMMUNE RESPONSE 
As soon as DCs and macrophages (antigen presenting cells; APCs) phagocytose either Mtb 
or BCG vaccine, they are enclosed in a lumen called as the phagosome, which is an 
invagination of the plasma membrane enclosing the bacterium. The mycobacteria are then 
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usually degraded by the acidification, proteolysis and peptides are produced to be presented 
on the surface of the APCs. The change that occurs in phagosome over the course of 
infection is called ‘maturation’ that generally results in fusion with lysosomes. The peptides 
are then recognized by T cell receptor bearing CD4 and CD8 T cells. This generates an 
immune response. These events are summarized below.        
 
PHAGOSOME MATURATION 
The immune response to bacterial invasion involves phagosome maturation, and fusion with 
the lysosome(27). Typically, a bacterium is endocytosed through receptor mediated uptake, 
and then resides within an endosomal, membrane bound, compartment, also termed a 
phagosome.  The phagosome then matures by a process of protein turnover, which 
eventually creates a hostile environment within the phagosome, with a low pH and high 
proteolytic activity, especially when fused to the lysosome, an organelle containing digestive 
enzymes(28).  The low pH is usually due to vATPase. After fusion with the lysosome, the 
bacteria are killed by one of the several mechanisms including, but not limited to, phagocyte 
oxidase, nitric oxide or proteolytic enzymes.  Degraded peptides are exported to multi-
vesicular bodies called MIIC compartments where they are assembled into the major 
histocompatibility complex (MHC) class II for transport to the cell surface and presentation 
to T cells (27).  There is a biochemical basis for the ability of Mtb and BCG to cause 
phagosome maturation arrest and these events are illustrated in figure-2. 
 
Initially, the phagosome is enclosed in rab5 positive early phagosomes.  Rab5 is a Ras 
associated protein, which is a Gtpase.  The phagosome then acquires additional proteins 
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mainly through the generation of PtdIns3P (PI3-phosphate) through the enzymatic action of 
phosphatidylinositol 3-kinase hVPS34.    
Figure-1: M. tuberculosis and BCG vaccine 
persist in infected macrophages by blocking 
Rab conversion and affecting Rab effectors. 
Type III phosphatidylinositol 3-kinase 
hVPS34- lipid kinase hVPS34 and its 
enzymatic product PtdIns3P are critical for 
the default pathway of phagosomal maturation 
into phagolysosomes. 
Mycobacteria block PtdIns3P production and 
thus arrest phagosomal maturation (29,30). 
 
THE VACUOLAR PROTON ATPASE  
The major mechanism that acidifies the phagosomal environment is the vATPase(31).  
Acidification is important for the activation of 
some enzymes that are required for the killing 
and breakdown of Mtb.  The other pumps that 
can influence lumen pH are Na+/H+ dependent 
proton pump and chloride channel (32,33).  
vATPase is a multi-subunit protein that 
assembles on the phagosomal membrane and 
pumps Hydrogen (H+) ions into the 
phagosomal lumen, thereby acidifying the 
lumen (Figure 2).  Acidification can be 
Rab conversion 
(Del Conte-Zerial
et al, Rink et al) Rab 7 Lysosome
Killing and Degradation
Rab 5
PI-3K
PI3P
EEA1
Rab 5PI3P
HRS
PI-3K (hvPS34)
EEA1HRS
APC Plasma membraneMycobacterium
Phagosome
Early endosome
Late endosome
Phagolysosome
Rab 5
GTP  GDP
LAM,phosphoinositedes
sapM
Biochemical basis for maturation arrest of BCG phagosomes
BLOCKADE
Figure 2: Effect of vacuolar proton ATPase 
(vATPase) on the regulation of pH inside 
phagosomes and the effect of bafilomycin on 
vATPase 
H+
vATPase
vATPase
H+
H+ pH
Antigen 
Presentation
Bafilomycin
pH
Antigen 
Presentation
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prevented by the addition of Bafilomycin, which specifically inhibits the action of vATPase 
by preventing the assembly of the V0 and V1 components on the phagosomal 
membrane(34,35). Bafilomycin therefore prevents acidification of phagosome lumen and we 
demonstrated in an earlier report that it neutralizes acidification of the phagosomes 
containing Mtb H37Ra within macrophages (36). 
 
TB MATURATION ARREST 
One major difficulty with controlling M.tuberculosis infection and enhancing vaccine 
efficacy through the use of BCG is that both strains are able to stall the maturation and 
fusion with lysosome (37-39).  Both BCG and Mtb secrete a phosphatase sapM  that 
dephosphorylates the PI3-phosphate on the phagosome membrane (40-42). In addition, both 
produce several metabolic analogs that compete with host enzymes during the initial events 
of PI3-phosphate synthesis.  Thus, phagosome maturation inhibition allows the virulent Mtb 
to survive and persist within human hosts. On the other hand, BCG vaccination is unable to 
induce a protective immune response against Tb because it is not processed by lysosomes 
(43-46) (47). In the absence of lysosomal fusion, the mycobacterial phagosomes have been 
found to cleave and produce peptides in situ, which is a novel emerging mechanism (48). 
This is the focus of our proposal. 
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ANTIGEN PRESENTATION
Once an invading pathogen is degraded in the 
molecules and shuttled to the cell surface 
cytokines IFNγ, IL-2 and others that act upon macrophages and DCs to enhance their 
function. This feedback activation of 
intracellular infections with Mtb and BCG vaccine 
human infection strongly indicate that it is the 
 
response that is critical for protection against tuberculosis, although CD8
role particularly against long term infection 
through HIV-1 infection, rapidly succumb to tuberculosis. It is possible that in humans
CD8+ T cells maintain immune 
infection recurs.  
 
Figure-3: Simplified model of antigen processing and presentation
into phagosome which fuses with lysosomes. Lysosomes degrade BCG vaccine and peptides 
are produced, which are loaded into MHC
 
 
lysosomes, antigens are loaded onto 
to be presented to T cells. T cells, in turn secrete 
 TH1 immune response is essential for the control of 
(49-53).  Evidence in animal models an
CD4+ IFN-γ+ T cell  dependent
+
 T 
(54,55).  Thus, humans depleted of CD4
surveillance and amplify both CD8+ and CD8
. BCG vaccine is taken up 
-II for presentation on cell surface to CD4 T cells.
MHC-II 
d 
 TH1  
cells also play a 
+
 T cells 
, 
+
 T cells when 
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TH1 IMMUNE RESPONSE 
The immune system can respond to infection in multiple ways.  An innate immune response 
provides a short lived immune response(56).  However, for long lasting protection, a cell 
mediated, adaptive immune response is necessary(57).  This response can provide protection 
against specific bacteria and infection and can be classified into two types, TH1 and TH2(57).  
A TH1 response activates antigen presenting cells such as macrophages and dendritic cells, 
and also stimulates B cells to produce opsonizing antibodies, while TH2 responses lead to 
mostly immunoglobulin responses.  It is believed that a strong TH1 response is needed to 
contain and eliminate Mycobacterium tuberculosis(49-53,58).  Tuberculosis infection is 
characterized by a reduced TH1 response, but sometimes correlates with increased TH2 
response in humans living in tropical regions.  Induction of a strong TH1 response controlled 
by T cells is essential for providing protection against infection by Mtb, and this protection 
is initially induced by Mtb infected dendritic cells.  When vaccination is used to induce 
immunity, DCs are involved. Dendritic cells, while capable of priming T cells may also get, 
infected with mycobacteria and show decreased maturation and activation (59-61).  Such an 
inhibition helps M. tuberculosis to survive within dendritic cells reducing immune 
responses, similar to the down-regulation of immune responses within macrophages.  Thus, 
both Mtb and BCG persist in host macrophages and DCs for years in a latent state. 
 
STATEMENT OF HYPOTHESIS 
The BCG vaccine phagosome is arrested at an immature phagosome stage, although it 
contains multiple protein components required for antigen processing assembly (48,62-64). 
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Thus, phagosomes appear to be peptide processing organelles (65). However, our previous 
observations showed that the pH of the phagosome is near neutral, suggesting weak 
proteolysis (36).  We therefore hypothesize that the efficacy of antigen processing in 
phagosomes may be dependent on pH regulating factors, although pH-independent, 
membrane associated processes may also be present. Thus, our aims are as follows. 
Aim I: Characterize the BCG phagosome for pH regulating processes that determine 
efficacy of antigen production. 
o Sub Aim IA: Characterize proton pumps that acidify the phagosome lumen 
o Sub Aim IB: Investigate if the phagocyte oxidase that regulates oxidants 
within phagosomes affects pH of the phagosome and thereby modulates 
antigen production 
o Sub Aim IC: Determine if phagosome pH can be modulated through the use 
of genetic mutants of BCG vaccine 
    
Aim II: Utilize proteomics to identify novel mechanisms that may mediate antigen 
processing of the BCG vaccine 
o Sub Aim IIA: Characterize the proteomics of BCG vaccine phagosomes  
o Sub Aim IIB: Investigate the proteomes of BCG phagosomes from 
macrophages & DCs  
o Sub Aim IIC: Investigate function of novel target proteins associated with 
BCG phagosomes  
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CHAPTER 2 
 
 
 
Characterize the BCG phagosome for pH regulating processes that determine 
the efficacy of antigen production 
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CHAPTER 2-1 
  
 
 
Characterize the BCG phagosome for pH regulating processes that determine 
the efficacy of antigen production 
 
Sub Aim IA: Characterize effects of proton pumps that acidify the phagosome 
lumen 
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INTRODUCTION 
Tuberculosis is the leading cause of death in mankind due to a single infectious agent. The 
causative organism, Mycobacterium tuberculosis (M.tuberculosis) is able to parasitize 
macrophages of man and animals and grow within them. Paradoxically, macrophages are 
also the cells that are capable of killing these organisms through acidification of bacterial 
phagosomes, oxidative processes and lysosomal degradation (66-69). M.tuberculosis has 
clearly evolved various mechanisms to neutralize these antimicrobial mechanisms. First, 
mycobacteria exclude vacuolar proton ATPase (vATPase) a major mechanism of phagosome 
acidification(36). Second, mycobacteria elaborate scavenging lipids, catalase-peroxidase and 
superoxide dismutases (SOD) to neutralize oxidants (70,71). Third, their phagosomes fail to 
fuse with lysosomes (72-74). The BCG vaccine used to prevent tuberculosis produces 
antigens largely similar to M.tuberculosis, having been derived from M.bovis, the pathogen 
that causes bovine tuberculosis. Interestingly, it seems to have inherited many immune 
evasion features of M.tuberculosis that enable it to sequester in immature phagosomes of 
macrophages.   
 
We investigated how immunogenic peptides are produced in macrophages and DCs.  It was 
known that, mycobacterial phagosomes could assemble MHC-II complexes that contained 
an epitope of immuno-dominant antigen-85B (Ag85B) which was then presented to the T 
cell hybridoma (BB7 T cells), resulting in IL-2 secretion (48). This in vitro model facilitated 
investigating mycobacterial antigen processing in APCs but, the molecular mechanisms 
remained unclear.  We then demonstrated that mouse macrophages infected with BCG 
vaccine presented Ag85B epitope to T cells, but the efficacy of presentation was reduced 
compared to macrophages infected with Mycobacterium tuberculosis H37Ra, an attenuated 
14 
mutant of Mtb H37Rv wild type
protease, Cathepsin-D, was required to 
was presented to T cells through 
figure-4 below.  However, d
phagosome level, significant 
the function of proteases in the phagosome
lumen at a near neutral pH? Is it possible to modulate 
antigen production can be enhanced
hypotheses.  
Figure-4: Hypothetical model of the importance of pH 
 
 (36). Additional studies described the key finding that a 
cleave Ag85B and produce an epitope 
the MHC-II pathway (36). These events are summarized in 
espite progress in our understanding of antigen processing at the 
questions have remained. What are the factors that determine 
? How does the BCG phagosome maintain its 
the pH of the phagosomes so that 
?  To address these questions, we developed two major 
during antigen presentation
 
which in turn, 
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OVERALL HYPOTHESIS  
From published literature it is known that a) the enzyme vATPase pumps protons into 
phagosomes to make it acidic(36), b) the NADPH oxidase (phagocyte oxidase or phox 
pump) secretes superoxide (O2*) that can potentially neutralize incoming protons, thereby 
increasing the pH (75), and c) BCG vaccine secretes a powerful enzyme, superoxide 
dismutase (SOD) that dissociates the superoxide into molecular oxygen and water, in a 
process that increases the pH(76). Thus, the intra-phagosomal pH appears to be the result of 
at least three converging and regulating factors. Since BCG derived Ag85B can be cleaved 
by Cathepsin-D only at an acidic pH, we proposed the initial hypothesis that peptide 
production in phagosomes is dependent upon pH regulation.  In this chapter, we specifically 
asked whether BCG phagosomes have a functional vacuolar proton ATPase pump and 
whether it influences antigen processing. 
 
METHODS  
C57BL/6 mouse derived macrophages and dendritic cells were purified as per previously 
published methods (METHODS 5-1). They were incubated with varying doses of the 
vATPase inhibitor, bafilomycin for 4 or 24 hrs and infected with BCG vaccine strain for 4 
hours post bafilomycin treatment. Macrophage or DC monolayers were washed and over 
laid with BB7 T cells, which release IL-2 when Ag85B epitope is presented from 
macrophages or DCs to T cells (METHODS 5-2). pH of the phagosome was rendered acidic 
using the calcium ionophore, nigericin. gfpBCG phagosomes are green due to neutral pH 
and were made acidic with nigericin. The effect of vATPase on the pH of the gfpBCG 
phagosomes was determined using bafilomycin blockade and then labeling the macrophages 
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with lysosensor-yellow-blue dextran (LSY) dye, revealing acidic phagosomes as blue and 
greenish yellow as near neutral pH phagosomes (METHODS 5-10). The BCG strain used 
for these experiments was BCG Tice (a sub strain of BCG Pasteur) and kindly supplied by 
our collaborator, Dr. D. Kernodle from Vanderbilt University. The growth and maintenance 
of BCG and cell cultures are described under Methods section. 
 
RESULTS 
Figure-5 demonstrates that treatment of macrophages and DCs with bafilomycin prior to 
BCG infection leads to a marked dose dependent inhibition of antigen presentation.  
Multiple experiments with both macrophages and DCs confirmed the observation (Table I).  
IN contrast global reduction of pH of macrophages using nigericin led to a marked increase 
in antigen presentation (Figure-6). 
In a previous study, we found that acidic pH enhanced the auto-catalytic degradation of 56 
kDa immature Cathepsin-D into 30 kDa active enzymatic form (36).  Furthermore, BCG 
phagosomes (pH 6.5) had reduced levels of active Cat-D while Mtb H37Ra phagosomes that 
acidified (pH 5), had increased levels of Cat-D. We also demonstrated by using siRNA 
knock-down that Cat-D was directly involved in cleaving Ag85B to produce an epitope that 
was presented to BB7 T cells.  
In order to further determine if bafilomycin induced increase of pH affected the generation 
of active forms of Cathepsin-D, BCG phagosomes were purified on sucrose gradients and 
analyzed using western blot for active and inactive forms of Cat-D. Macrophages were 
activated with IFNγ as a positive control and in addition, phagosomes containing latex beads 
were purified from naïve macrophages as a negative control. Figure 7 demonstrates that 
17 
 
purified gfpBCG phagosomes from bafilomycin treated macrophages show reduced levels of 
active 30 kDa Cat-D compared to phagosomes from untreated or IFNγ activated 
macrophages. Latex beads that mature quickly into lysosomes showed active Cat-D even 
without macrophage activation. Finally, the pH of the phagosomes was estimated using the 
fluorescent dye LSY that co-localizes with gfpBCG phagosomes yielding a blue color when 
the phagosome lumen pH is acidic. Figure 8A and B illustrate that bafilomycin treatment of 
macrophages, increases the pH of gfpBCG phagosomes so that the proportion of green BCG 
phagosomes was higher. These data together implicate the vATPase as one major 
mechanism of acidification of BCG phagosomes in macrophages.   
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Figure-5: Bafilomycin, an inhibitor of vacuolar proton ATPase (vATPase) leads to 
reduced antigen 85B presentation in macrophages and dendritic cells. Primary murine 
macrophage or dendritic cells were plated into 24 well plates, treated with varying doses of 
bafilomycin for 24 hours, infected with BCG Tice for 4 hours, washed and then overlaid 
with BB7 T cells. IL-2 secreted by T cells into the supernatant was measured using sandwich 
ELISA (data from one of 3 similar experiments). 
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Table I: Bafilomycin blockade of vacuolar proton ATPase in two types of antigen 
presenting cells inhibits Ag85B presentation in vitro. Macrophages and DCs derived from 
C57BL/6 mice were tested for the ability to present Ag85B to BB7 T cells and the inhibitory 
effects of bafilomycin were measured using levels of IL-2 as a parameter.  
  
Cell Type Bafilomycin pg/ml IL-2 SD n
0 206.60 47.68 2
13 nM 38.84 0.00 2
26 nM 43.89 5.28 2
52 nM 63.64 46.25 2
0 78.35 14.90 2
13 nM 39.06 2.17 2
26 nM 51.13 11.79 2
52 nM 58.81 10.86 2
0 170.00 9.00 2
13 nM 52.01 6.21 2
26 nM 64.30 7.45 2
52 nM 71.33 5.59 2
0 6107.84 2166.96 2
13 nM 5728.86 3007.87 2
26 nM 3886.22 2799.95 2
52 nM 3173.99 748.50 2
0 2605.51 1233.64 2
13 nM 1005.21 227.92 2
26 nM 802.35 14.34 2
52 nM 658.09 186.48 2
0 2605.51 1233.64 2
13 nM 1016.48 247.04 2
26 nM 1281.32 168.94 2
52 nM 1671.27 379.33 2
0 7631.95 2372.56 2
13 nM 6506.43 924.08 2
26 nM 4480.83 314.19 2
52 nM 2056.64 78.55 2
0 2004.37 0.00 2
13 nM 1042.40 76.50 2
26 nM 1417.69 14.34 2
52 nM 1605.90 86.07 2
0 873.1553 60.657 2
30 nM 880.9536 138.59 2
0 115.3724 9.2659 2
30 nM 112.2388 18.532 2
Primary Dendritic Cell
Primary Macrophage Cell
Primary Macrophage Cell
Primary Macrophage Cell
Primary Dendritic Cell
Primary Dendritic Cell
Primary Dendritic Cell
Primary Macrophage Cell
Primary Dendritic Cell
Primary Dendritic Cell
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Figure-6: Nigericin, a calcium ionophore that reduces organelle pH in macrophages, 
enhances antigen presentation in BCG infected macrophages.  Primary murine 
macrophages were plated into 24 well plates, treated with varying doses of nigericin for 4 
hours, infected with BCG Tice for 4 hours, washed and then overlaid with BB7 T cells for 
IL-2 assay as in Figure-5 (one of 3 similar experiments shown).  
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Figure-7: Bafilomycin treatment 
lumen and prevents activation of Cathepsin
line was treated with either 100 nM bafilomycin 
activator, followed by infection with 
from naïve macrophages. Macrophages were washed and 
were purified on sucrose gradients
Cathepsin-D. Data show that 
enrichment of active 30 kDa band 
treated macrophages. As expected
of cat-D, even without macrophage activation. 
results is shown. 
 
of macrophages increases the pH of the phagosome 
-D. C57BL/6 derived BMA macrophage cell
for 18 hrs or 50 ng/mL IFNγ
BCG for 24 hrs. Control phagosomes were latex beads 
BCG or latex bead 
 and analyzed using western blot with antibody to 
56 kDa Cat-D inactive form is present in BCG that show 
after IFNγ treatment, but remain inactive in bafilomycin 
, phagosomes containing latex beads contain
One of two separate experiments
 
 
 as a positive 
phagosomes 
 active forms 
 with similar 
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Figure-8A: Bafilomycin treatment increases the pH of the phagosome lumen and prevents 
acidification. The fluorescent dye Lysosensor yellow-blue dextran remains largely green 
in gfpBCG phagosomes after bafilomycin treatment. C57BL/6 derived macrophages were 
treated with 100 nM bafilomycin (vATPase inhibitor) for 18 hrs followed by 60 min 
treatment with nigericin and infection with gfpBCG for 4 hrs. Macrophages were washed, 
incubated in fluormount and phagosomes imaged using a Nikon microscope with metaview 
software. gfpBCG co-localizing with LSY were scored blue vs. green bacteria and per cent 
co-localizing gfpBCG determined in 100 macrophages in 2 separate experiments. 
Quantitation is shown in Figure 8B.   
None Bafilomycin
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Figure-8B: Bafilomycin treatment increases the pH of the phagosome lumen and 
acidification. gfpBCG phagosomes
software. gfpBCG are generally green since 
Prior treatment of macrophages with nigericin makes them acidic, while treatment with 
bafilomycin makes them neutral. 
(acidic) vs. green (neutral) bacteria and per cent 
macrophages of triplicate chambers per experiment in
determined using t test).Excitation
Invitrogen, Molecular Probes.
 
 
 
 
 were imaged using a Nikon microscope with metaview 
BCG associated phagosomes are near neutral. 
Number of gfpBCG fluorescing with LSY were scored blue 
green gfpBCG determined in 100 
 2 separate experiments (p value 
 480 nm and emission 530 nm. LSY dextran was from 
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Chapter 2-2 
  
 
 
Characterize the BCG phagosome for pH regulating processes that determine 
the efficacy of antigen production 
 
Sub Aim IB: Investigate whether the phagocyte oxidase (phox) that secretes 
superoxide into phagosomes affects pH of the phagosome and thereby 
modulates antigen production 
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INTRODUCTION 
There are several mechanisms that APCs can use in order to defend against invading 
pathogens.  The vATPase induced acidification of macrophages and dendritic cells leads to 
the generation of active forms of Cathepsin-D, that by itself can be bactericidal as well as 
proteolytic(36). In addition, a multi-component NADPH oxidase complex (phox) 
accumulates on phagosome membrane soon after phagocytosis of mycobacteria (77).  The 
phox complex has many subunits, including the major components  p22phox, p47phox , p67phox  
and p91phox (78-81). Proper assembly of these subunits on the membrane of the phagosome 
leads to the superoxide-radical O2- being pumped into the phagosomes. Superoxide by itself 
is bactericidal for a variety of microbes but in the presence or iron and halide ions leads to 
the formation of more bactericidal radicals like hydroxyl radical, H2O2 and hypochlorous 
acid. Superoxide is the lead oxidative radical produced from phox complex and can alter the 
pH of the phagosome through two mechanisms.  In one mechanism superoxide combines 
with protons pumped in from vATPase, and forms hydrogen peroxide that can neutralize the 
pH.  In a second mechanism it can also spontaneously dismutate into oxygen and water to 
raise the lumen pH. It has been reported that phox can control the pH of DCs and affect 
cross-presentation, a major route for MHC-I type antigen presentation (82). However, its 
role in the regulation of antigen presentation through MHC-II has remained unclear. 
 
HYPOTHESIS  
In this chapter, we hypothesized that inhibition of phox activity 
using the NADPH oxidase inhibitor, diphenylene-iodonium chloride, 
would reduce pH and lead to enhanced antigen presentation. 
O2
phox
phox
pH Antigen 
Presentation
DPI
pH
Antigen 
Presentation
O2
-
O2
Figure-9: Proposed action of phox on 
the regulation of pH and the likely 
effect of DPI 
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METHODS  
C57BL/6 mouse derived macrophages and dendritic cells were purified as per previously 
published methods (METHODS 5-1). They were incubated with varying doses of the 
phagocyte oxidase inhibitor diphenylene iodonium chloride (DPI) for 24 hours and infected 
with BCG vaccine strain for 4 hrs. Monolayers of cells were washed and over laid with BB7 
T cells, which release IL-2 when Ag85B epitope is presented from macrophages or DCs to T 
cells (METHODS 5-2). IL-2 was quantitated using sandwich ELISA. 
 
RESULTS AND DICSUSSION 
Figure-10 illustrates that the inhibition of phox complex using DPI led to a surprising 
decrease in antigen presentation by both DCs and macrophages. We had anticipated in our 
initial hypothesis that phox secreted superoxide would either neutralize the protons being 
pumped in by vATPase or would rapidly dismutate into oxygen and water. Either of these 
events would lead to a neutral pH inside phagosome. Thus, inhibition of the phox enzyme 
through DPI was expected to reduce the pH of the phagosome and lead to enhanced antigen 
presentation through activation of enzymatically active Cathepsin-D.  The fact that DPI 
treatment of macrophages and DCs reduced antigen presentation suggests that the pH of the 
BCG phagosome was not rendered acidic.  Although not anticipated, our observation 
appears inconsistent with the recent report that inhibition of the phox through DPI does not 
significantly affect the phagosomal pH, when latex beads are used to measure the pH of the 
phagosomes in macrophages (83).  However, we used live BCG as a phagosome in contrast 
with inert latex beads in macrophages, and it was possible that the bacterial derived factors 
27 
 
could change the intracellular pH. We therefore propose that BCG derived superoxide 
dismutase (SOD), which dismutates superoxide anion, interacts with other oxidants within 
the phagosome, eventually raising the pH, despite ongoing acidification of the lumen 
through vATPase. That, the BCG phagosomes are near neutral was consistent with this 
hypothesis (36).  
 
We conclude therefore that both vATPase and phox pumps can alter the pH of the 
phagosome while BCG secreted SOD enzyme also perhaps plays a significant role in the 
modulation of lumen pH.   
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-10: Inhibition of phagocyte oxidase in macrophages and DCs with diphenylene-
iodonium chloride leads to decreased antigen presentation. Macrophages and DCs were 
incubated with varying doses of DPI for 4 hrs followed by infection with BCG for another 4 
hrs (MOI 1:1). Washed monolayers were overlaid with BB7 T cells and IL-2 release 
measured after 18 hrs (Mean± SD; one of 2 separate experiments with similar data shown; 
all values for DPI treatment are significant compared to untreated) 
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Chapter 2-3 
  
 
 
Characterize the BCG phagosome for pH regulating processes that determine 
the efficacy of antigen production 
 
Sub Aim IC: Determine if phagosome pH can be modulated through the use of 
SOD mutants of BCG vaccine   
30 
INTRODUCTION 
Data shown in chapters 2-1 and 
led to inhibition of antigen production thereby indicating
antigen production.  Thus, there 
of the phagosome and affect
role played by the BCG vaccine itself, sinc
dismutase (SOD) that dissociates superoxide into oxygen and water. Unde
circumstances, BCG infected macrophages 
produced and presented to T cells
We therefore speculated that 
secreted SOD was inactivating 
sufficient to acidify the lumen. In this study
 
HYPOTHESIS  
In this chapter, we hypothesized that BCG 
induced SOD may play role 
determining intra-phagosomal pH perhaps 
by dissociating superoxide leading to 
molecular oxygen and water.
speculated that molecular oxygen may 
neutralize protons coming from 
vATPase pump, so that the net effect of 
SOD is neutralization of the pH of the 
 
2-2 showed that blockade of vATPase and phox enzymes 
 that pH determines the level of
are at least two regulatory mechanisms that
 the antigen production.  However, these events 
e BCG secretes a powerful enzyme superoxide 
r physiological 
show minimal amounts of Ag85B
, which we hyppthesize is because of a neutral pH 
under natural circumstances of infection of macrophages, 
superoxide from phox enzyme and vATPase was not 
, we examined the role of SOD. 
in 
  We also 
the 
Figure-11: BCG secretes copious Superoxide 
dismutase (SOD) and raises pH which decreases 
cathepsin-D activation and thereby antigen 
production  
 
 
 control the pH 
excluded the 
 being 
(36). 
BCG 
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phagosome lumen.   We therefore hypothesized that a BCG vaccine candidate that does not 
secrete SOD or is defective in secreting SOD should be unable to modulate pH of the 
phagosome and thereby adversely affect antigen production.  
 
SUPEROXIDE DISMUTASE 
Mycobacteria contain genes encoding for superoxide dismutase (SOD)(70,71).  Superoxide 
dismutase is a secreted enzyme that spontaneously dismutates into molecular oxygen and 
water (hence the name). SOD is an essential gene in mycobacteria and can only be 
suppressed through genetic manipulation strategies. BCG strains lacking the ability to 
produce or secrete SOD were formed from a parent BCG-Tice strain (a kind gift of Doug 
Kernodle Ph.D., Vanderbilt University).  Three mutants from a parent strain of BCG-Tice 
were made, BCG∆SODA, BCG∆SecA2 and BCG∆SODASecA2.  These strains are 
respectively, BCG that has SOD suppressed, BCG that has the secA apparatus disrupted and 
BCG that has both SOD suppressed and SecA2 disrupted. SecA is required for secretion of 
SOD from mycobacteria, and therefore knocking out this gene leads to a lack of secretion of 
SOD from BCG into the lumen of phagosomes. These strains were constructed by inserting 
a hygromycin resistance vector (hygR) into the genes encoding SOD or SecA, thereby 
inactivating the target gene (70,84,85). 
 
METHODS 
Macrophages and DCs were infected with wild type Tice BCG and the mutants and 
analyzed for the induction of IL-2 using the standardized antigen presentation system 
(METHODS 5-2). Macrophages were also infected with Tice and mutant strains and 
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phagosomes of the bacteria purified using sucrose gradients (METHODS 5-7). The 
phagosomes were analyzed for the content of Cathepsin-D protease to determine if the 
phagosomes were acidic enough to generate active forms of Cathepsin-D (METHODS 5-3 
and 5-4). Furthermore, C57BL/6 mice were immunized subcutaneously with BCG and an 
SOD-deficient mutant strain, and 2 weeks later, the spleen T cells were analyzed for CD4+ T 
cells secreting IFNγ using flow cytometry. 
 
RESULTS AND DISCUSSION 
We demonstrated earlier that preventing acidification of the phagosomes through 
bafilomycin treatment inhibits antigen production.  Paradoxically, inhibition of phagocyte 
oxidase activity via DPI also decreased antigen presentation from BCG vaccine infected 
macrophages. These data together suggest that pH is a critical determinant of the phagosome 
that determines the antigen production. It is obvious that enhancing antigen production will 
make a stronger BCG vaccine, but it is difficult to modulate the pH of the macrophage or 
phagosome pH through chemical intervention without causing toxicity.  In this study, we 
used genetically modified mutants of BCG Tice strain   BCG∆SODA, BCG∆SecA2 and 
BCG∆SODASecA, to infect the macrophages. The hypothesis was that, BCG strains secrete 
copious amounts of SOD enzyme which can detoxify the superoxide and enhance 
phagosome pH.  Mutants that have reduced SOD would be unable to modify pH and would 
therefore be more susceptible to antigen processing and presentation. 
 
Figure 13 illustrates that the SOD mutants were indeed processed better by the macrophages 
and DCs, which presented Ag85B better, with elevated IL-2 levels.  In order to determine if 
Figure-12: Loss of SOD increases 
antigen presentation by macrophages 
and DCs. 
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SOD altered the pH of the phagosome and affected proteolysis, the phagosomes of wild type 
Tice and mutants were then purified from macrophages and analyzed for the enzyme 
Cathepsin-D using western blot. In our previous studies, we demonstrated that Cat-D was 
the major protease that produced Ag85B for presentation to BB7 T cells. In this study 
(Figure 14), the active form of Cat-D was enriched within the phagosomes of the mutants 
BCG∆SODA and BCG∆SecA2 compared to the wild type Tice phagosomes. This implied 
that antigen production by macrophages with the latter mutants correlated with the presence 
of active Cat-D (30 kDa). Since the generation of 
active Cat-D (30 kDa) from immature Cat-D (56 
kDa), is a pH dependent process (36), this suggests 
that the SOD enzyme from BCG directly affects 
the pH of the phagosomes and affects levels of 
active Cat-D.  The ability of SOD mutants to 
generate better immune responses at the level of 
macrophages was also reflected in mice. Mice immunized with SOD mutants were found to 
respond with increased numbers of IFNγ positive CD4+ T cells through Elispot analysis 
(Figure 15).  
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Figure-13: The superoxide dismutase (SOD) defective mutant strains of BCG 
strain (BCG∆SODA, and BCG
macrophages to result in enhanced 
or DCs from C57BL/6 mice were infected with either wild type Tice or mutant 
equal MOI (1:1), incubated for 4 hrs, 
was quantitated using sandwich ELISA (
values obtained by using student t test.
 
 
 
∆SODASecA2) are more effectively processed by 
Ag85B presentation to T cells in vitro. 
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one of four similar Elisa experiments s
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Figure-14: The phagosomes of superoxide dismutase (SOD) defective mutant strains of 
BCG Pasteur sub strain Tice, (BCG∆SODA, BCG∆SODASecA2) contain the more mature 
form of Cathepsin-D. Macrophages from C57BL/6 mice were infected with either wild type 
Tice or mutant strains at an equal MOI (1:1), incubated for 24 hrs, washed and phagosomes 
purified using sucrose gradients. Equal amounts of proteins were loaded onto a 10% SDS 
gel and blotted. Bands were then analyzed for Cathepsin-D using western blot with antibody 
to Cat-D and antibodies to vATPase and iNOS as positive controls. One of two separate 
similar experiments is shown.  
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Figure-15: The SOD defective mutant strain
more immunogenic in mice
mutant strain at 106 CFU per subcutaneous dose and on
splenic T cells were assayed for 
show that the mutant strain induces a stronger IFN
Tice.  One of two separate but 
 
 
 of BCG sub strain Tice (BCG
. C57BL/6 mice were infected with wild type Tice or SOD 
 7 and 14 days after infection, 
IFNγ secreting CD4+ T cells using flow cytometry. Data 
γ
+
 CD4+   T cell response than wild type 
similar experiments is shown.  
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CHAPTER-2 
GENERAL DISCUSSION 
Role of pH as a regulatory mechanism for antigen production 
The phagosomes of BCG vaccine within macrophages and DCs seem to be regulated by 
three separate, but overlapping mechanisms that affect the overall pH of the lumen. Two of 
these mechanisms are innate mechanisms of the host macrophages, namely vATPase that 
assembles as a multimeric enzyme on phagosomes to acidify, and the multimeric phagocyte 
oxidase that also assembles on the phagosome, when BCG vaccine invaginates into the 
plasma membrane forming the phagosome. While vATPase acidifies, phox enzyme 
alkalinizes the lumen and thus the net pH of the lumen appears to be determined by the 
bacterially derived enzyme SOD. SOD has been thought to be an immune-evasive factor 
secreted by BCG vaccine that detoxifies the superoxide and in doing so causes the pH to 
again become neutral. It is noted here that there are many other pumps that can affect the 
phagosome pH and this is a simplified scenario of the complex environment.  Blockade of 
phox utilizing DPI was able to markedly inhibit antigen presentation, and it is possible that 
there are other factors at play. For example, investigators argue that oxidants inactivate 
cathepsins (86)   Nevertheless, disruption of the SOD enzyme in the BCG vaccine led to an 
enhanced immunogenic phenotype of BCG vaccine. This argues that the lumen pH may well 
be regulated by vATPase and phox but bacteria like BCG also seem to have evolved to 
cause immune evasion through SOD.  BCG is therefore able to overcome the effects of 
vATPase and phox.  Together, these data support our contention that an enhanced 
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understanding of the pH regulatory mechanisms of the phagosomes will enable us to design 
better vaccination strategies for tuberculosis.  
Figure-16: Mechanisms of pH regulation in phagosomes affect antigen production in 
macrophages and dendritic cells.  
BCG
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CHAPTER 3 
 
 
 
Aim II  
Utilize proteomics to identify novel mechanisms that may mediate antigen 
processing of the BCG vaccine 
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CHAPTER 3-1  
 
 
 
Utilize proteomics to identify novel mechanisms that may mediate antigen 
processing of the BCG vaccine 
 
Sub Aim IIA: Characterize the proteins of BCG vaccine phagosomes through 
proteomics 
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INTRODUCTION 
When latex beads or bacteria are internalized into macrophages they are enclosed within a 
membrane bound compartment called the phagosome(52,53). Desjardin group did a 
comprehensive analysis for the proteins associated with the latex bead phagosome, and 
found numerous proteins associated with 
the phagosome, many with undefined 
functions (87,88). Since particles 
phagocytosed by macrophages and DCs are 
destined for degradation in lysosomes, the 
phagosomes move through successive 
stages to lysosome in a process called 
maturation or phagosome-lysosome fusion. 
This process is regulated in turn by a series 
of proteins like rabs and SNARES (89-91). 
 
Compared to the phagosomes containing 
latex beads, the bacterial phagosome is 
more complex because host interaction with bacteria recruits more proteins into the 
phagosome.  While the phagosome can potentially contain hundreds of proteins, identifying 
all the proteins associated with the bacterial phagosome and differentiating them on the basis 
of host and bacterial origin is cumbersome using traditional techniques such as western 
blotting.  Our collaborator, Dr. Qing Bo Li – University of Illinois at Chicago, developed an 
innovative process of peptide mapping using proteomics. In this process phagosomes 
Figure-17: Virtual phagosome demonstrating numerous 
proteins on phagosome surfaces. 
http://www.dsv.cea.fr/thema/lcp/phagosome/phago2_fr.
htm  
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purified from macrophages are subjected to two dimensional gel electrophoresis and spots 
are excised and subjected to Mass spectrophotometry analysis.  Proteins are identified on the 
basis of their amino acid sequence and quantities compared using a software program. These 
methods have been published (92-94).  
 
HYPOTHESIS 
Since we found that BCG vaccine phagosomes had a near neutral pH and three mechanisms 
regulated the internal pH, we hypothesized that perhaps the phagosome also contains 
additional proteases that mediate generation of peptides leading to generation of immune 
responses.   
 
METHODS 
We previously published methods to purify mycobacterial phagosomes from mouse 
macrophage cell lines (36). In this study, we infected the C57Bl/6 mouse derived BMA.A1 
macrophage like cell line with BCG vaccine and wild type Mtb H37Rv, in addition to 
∆fbpA mutant, a novel lysosome-fusion competent vaccine comparable to BCG (95) 
(Figure-18). After 24 hrs of infection, the phagosomes were purified using sucrose gradients 
and shipped to the laboratory of Dr. Li, UIC, where, a proteomic analysis was performed. 
The data were analyzed and presented in a graphical format (additional detailed procedures 
are outlined in METHODS 5-9). 
 
 
 
43 
 
RESULTS AND DISCUSSION 
The proteomic analysis found over three-hundred proteins associated with each of the three 
species of mycobacterial phagosomes.  Statistical analysis was performed to compare the 
proteins from purified phagosomes containing one of three mycobacterial strains (BCG, 
∆fbpA and wild type H37Rv). We first determined that proteins (e.g., rabs) that are known to 
be associated with endosome-phagosome traffic were present in phagosomes. Interestingly, 
several proteins of hitherto undefined function were also differentially enriched on the 
phagosomes. These are shown as the three distal groups in Figure-19 and the putative 
functions of these proteins are reproduced from the literature in Table-I. We observed that 
Nicastrin was enriched on Mtb H37Rv phagosomes compared to BCG and ∆fbpA.  
However, Nomo, a protein that associates with nicastrin was more enriched on BCG 
phagosomes (96-98). Although subtle variations in the quality of phagosomes prepared 
could affect the relative amounts of proteins on phagosomes, it was interesting to find that of 
the 300 or so proteins on phagosomes, components with protease activity like nicastrin were 
enriched. Thus, proteomic analysis identified certain proteins with protease function in 
mycobacterial phagosomes. This assumed significance since previous reports indicated that 
nicastrin typically associates with two other components, APH and presenilin to form the γ-
secretase complex.  The γ-secretase complex is a membrane-associated protease and 
suggested to recycle and remodel phagosomes (99). The data suggested a novel hypothesis, 
that nicastrin and associated proteins could play a proteolytic role associated with the 
phagosomes. 
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Figure-18: Outline of the procedure used to purify the phagosomes which were then 
subjected to proteomic analysis (100) 
 
Proteomic analysis
Macrophages (BMA cell line 
from C57Bl/6 mice) were 
infected with H37Rv, ∆fbpA or 
BCG-Pasteur
Phagosomes 
collected and 
purified
Samples frozen 
in SDS sample 
buffer and 
shipped to 
UIC, Chicago
Mass spectroscopy 
analysis performed, data 
tabulated and statistical 
analysis performed
BMA cell line: Kovacsovics-Bankowski M, Rock KL. 
Science. 1995 Jan 13;267(5195):243-6.
• BCG vaccine -Pasteur 
• Wild type M.tuberculosis
H37Rv 
• ΔfbpA strain-KO strain
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Figure-19: Scatter plot of the T2 values of over 300 proteins quantified in the phagosomes 
(Φ) of the BCG-, ∆fbpA-, and Mtb H37Rv-infected macrophages. The x,y,z axis represent 
the different strains of mycobacteria utilized for this experiment.  Each circle represents a 
protein, and the size of the circle represents the abundance of the protein on the phagosome 
.  The color indicates the fold change of the protein over the phagosomes of the other 
strains. The marker size is proportional to the square-root of the averaged (5 repeats of 
each phagosomal sample) intensity of that protein in the three phagosome samples as 
determined by mass spectroscopy (reproduced from Li et al, (92)). 
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Table-II: Proteins relatively enriched on BCG phagosomes are noted with putative 
function identified from protein data base. There were two studies published, from which 
the enriched proteins were identified (92-94,101). 
 
 
 
 
 
 
 
 
 
Proteins enriched on BCG phagosome This study Lee et al
asparagine synthetase +
chaperonin containing TCP1 +
Cytochrome B5 +
Nicastrin + +
Nomo (pM5) +
peptidylprolyl isomerase B (cyclophilin B) +
Rab 5 + +
Ribosomal Component Proteins + +
Recycling 
nutrients
Nicastrin
binding 
partner
Chaperone for vATPase
PLoS One. 2010 (11):e13930
(134) 
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CHAPTER 3-2 
 
 
 
Utilize proteomics to identify novel mechanisms that may mediate antigen 
processing of the BCG vaccine 
 
Sub Aim IIB: Compare the proteomics of BCG phagosomes derived from 
macrophages and dendritic cells  
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INTRODUCTION 
While macrophages and dendritic cells are both capable of processing and presenting 
peptides to CD4+ and CD8+ T cells, it has been known that only DCs are able to cross-talk 
with naïve T cells and prime them for antigen specificity and expansion into effecter T 
cells(49,50,52,53). We wondered whether phagosomes of DCs and macrophages are 
comparable. Since we identified in our previous chapter that some proteases were enriched 
in the mycobacterial phagosomes, we sought to understand whether similar proteins were 
present in phagosomes purified from DCs. In this study, we hypothesized that phagosomes 
derived from macrophages and DCs were similar in protein content, at least with respect 
with some proteases. 
METHODS 
Methods were similar to those described in the previous chapter but the phagosomes were 
fractionated from CY-15, a dendritic cell line provided by Dr. Blankenstein (102). For 
comparison, phagosomes of three species of mycobacteria (BCG, wild type H37Rv and 
∆fbpA) were purified at the same time from BMA.A1 macrophage cell line. All infections 
and incubation conditions were identical, other than the cell line.   
RESULTS AND DISCUSSION 
DC dericed phagosomes containing BCG, wild type H37Rv and ∆fbpA were analyzed and 
found to contain proteins largely similar to those found in macrophages. Table-III & Figure-
20 illustrate proteins that were commonly found among phagosomes from two cell lines.  It 
was noted that nicastrin was again found to be enriched on the mycobacterial phagosomes of 
DCs.  
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Table III:  An abridged list of proteins enriched on the phagosomes containing BCG 
vaccine, wild type M.tuberculosis (shown as Rv) and ∆fbpA mutant (designated as KO) 
analyzed using proteomics. The abundance of nicastrin is highlighted. As in Figure-19 over 
350 proteins were analyzed and the numbers indicate the relative expression of proteins 
associated with phagosomes containing various strains of mycobacteria and within either 
dendritic cells (DCs) or macrophages (MPs).      
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Figure-20: Proteins enriched on the phagosomal membranes of mycobacterial 
phagosomes (BCG vaccine, M. tuberculosis and ∆fbpA mutant) are illustrated. The 
proteins were identified from a more exhaustive list of proteins analyzed on phagosomes of 
mycobacteria, illustrated in the Table II. Putative functions are highlighted with arrows. 
  
Regulates pH and 
peptide production in situ
Produces antigenic
Peptides in situ
peptide transporter for MHC-I
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CHAPTER 3-3 
 
 
 
Utilize proteomics to identify novel mechanisms that may mediate antigen 
processing of the BCG vaccine 
 
Sub Aim IIC: Investigate the function of target protein (nicastrin) identified 
through proteomics 
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INTRODUCTION 
Tuberculosis is the leading cause of death due to an infectious disease and BCG is the only 
approved vaccine for humans. BCG gives variable protection against tuberculosis depending 
upon geographic regions and the variation has been thought to be due to the loss of some 
immunogenic antigens, strain variation and population immunity factors. In addition, earlier 
studies show that the BCG vaccine sequesters within early endosomes, which do not fuse 
with lysosomes (103). Since peptide processing and presentation through MHC-II is 
essential, this suggested that antigen presenting cells (APCs) like macrophages and dendritic 
cells would be deficient in presenting MHC-II dependent peptides from BCG. Indeed, 
phagosomes of BCG were near neutral in pH due to interplay  of complex factors involving 
vATPase and phagocyte oxidase enzyme and as a consequence, intra-phagosomal cathepsin-
D was inactive (36). Furthermore, using a T cell hybridoma specific for a major secreted 
antigen from BCG antigen 85B, we found  that APCs infected with BCG showed a 
decreased antigen presentation (36). Curiously, the wild type Mycobacterium tuberculosis 
(Mtb) was the first pathogen reported to evade phagosome-lysosome fusion in macrophages 
(37-39). It is now evident that BCG vaccine also has immune evasion mechanisms, that 
enable the bacterium to be sequestered within non acidic phagosomes (104-106) (Chapter 1).  
 
Tuberculosis is an important disease for which efficient vaccination strategies have been 
sought. We therefore initially analyzed alternative mechanisms of antigen processing within 
macrophages that facilitate immune recognition of the vaccine or wild type pathogen. We 
analyzed the proteome of the phagosomes of BCG as well as the wild type Mtb H37RV, 
purified from mouse macrophages (Chapter 3.1, 3.2). We found that nicastrin, a component 
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of the enzyme γ-secretase, was enriched on the phagosomes of the wild type Mtb and to a 
lesser extent on BCG vaccine phagosomes.  
 
γ-SECRETASE  
γ-secretase is a multi-subunit membrane-associated enzyme complex known to participate in 
Notch signaling and cleavage of amyloid precursor protein (APP).  The complex consists of 
nicastrin, presenilin and APH (98,107,108).  Previous studies have focused on the role of γ-
secretase during Alzheimer’s disease; γ-secretase cleaves the Amyloid Precursor Protein 
(APP) and the byproduct, amyloid β (Aβ), is the primary component of amyloid plaques that 
cause the disease(109,110).  γ-secretase cleaves the transmembrane portion of APP, 
producing the 4 kDa Aβ peptide, which is implicated in the progression of Alzheimer’s 
disease.   
 
 
 
 
 
 
 
 
γ-Secretase has also been implicated during Notch signaling, a critical pathway of cell 
development  (111,112).  Notch signaling involves activation and internalization of Notch 
receptors, which bind to ligands. Once internalized, the ligand-receptor complex is 
Figure-21:  Membrane structure of γ-secretase (97) 
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endocytosed and the complex is cleaved by γ-secretase, releasing a signaling peptide that 
translocates to the nucleus for activation of target genes.  Finally, a recent study has 
demonstrated that γ-secretase is a component of the phagosome, and proposed that it may 
remodel the phagosome and recycle its components. In addition, γ-secretase is up-regulated 
by IFN-γ while, two additional substrates of γ-secretase, CD-44 and CD-91 are known to be 
involved with phagocytosis (112). 
 
HYPOTHESIS 
Previous chapters (Chapter 3.1,3.2) demonstrated that nicastrin and Nomo are associated 
with mycobacterial phagosomes. Interestingly, BCG vaccine secretes a number or proteins 
including Ag85A and B into the phagosome lumen. Since nicastrin associates with APH and 
Presenilin to form the γ-secretase complex, which is a membrane associated protease, we 
speculated that nicastrin or γ-secretase components can fortuitously cleave BCG vaccine 
derived proteins. Thus, we hypothesized that γ-secretase complex may generate immune 
responses. 
 
METHODS  
C57BL/6 mouse bone marrow derived primary macrophages and DCs were cultured and 
infected with BCG (Pasteur) or wild type M. tuberculosis as previously described 
(METHODS 5-2). They were overlaid with BB7 T cells specific for Ag85B (kind gift of Dr. 
Harding, CWRU) and IL-2 secreted in response to Ag85B was quantitated using ELISA. 
siRNA blockade of γ-secretase was carried out using specific siRNAs obtained from Santa 
Cruz Biotechnology against nicastrin, APH and presenilin and the control was a scrambled 
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siRNA supplied also by the manufacturer. Chemical inhibition of γ-secretase was carried out 
using L-685458. 
 
Immunoflourescence analysis for γ-secretase and localization on BCG phagosomes  
APCs were infected with gfpBCG or gfpMtb (H37Rv), washed, fixed, counterstained  and 
scored for immunofluorescence co-localization with antibodies directed against the 
components of the γ-secretase as per published procedures (2) (8)(113,114) (METHODS 5-
6).  
 
Membrane or cytosol localization for Nicastrin  
Macrophages and DCs were either left naïve or treated with L685458 in 24 well plates, 
infected with BCG and washed. Monolayers were washed with PBS, extracted with 0.05% 
digitonin, 0.5% sucrose in PBS-EDTA (DSPE) buffer for 15 min to obtain cytosol fraction, 
which was then ultra-filtered and stored. The monolayer was washed with cold DSPE three 
times and the membrane fraction solubilized with 0.1% tritonX-100 in PBS for 15 min and 
stored until western blot analysis. 
 
Mouse experiments  
BM derived, CD11c bead purified DCs were infected before or after treatment with 
L685,458 (1 µg/mL and 10 µg/mL for 4 hrs) with BCG, washed and 106 DCs per mouse 
injected i.p. into C57BL/6 mice, using 4 mice per group. Untreated DCs injected into mice 
were negative controls. After 7 days, spleens were removed and IFNγ + CD4+  T cells were 
detected using flow cytometry for intracellular cytokines and by ELIPOST analysis with 
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Ag85B re-stimulation (8). All animal procedures were conducted under approved 
institutional protocols.  
 
RESULTS AND DISCUSSION 
γ-secretase components are enriched on mycobacterial phagosomes: We previously 
reported that Nicastrin is enriched on the phagosomes of wild type strain of Mtb (H37Rv) 
using Mass-spectrometry analysis of purified phagosomes from mouse macrophages 
(Chapters 3-1, 3-2). To determine whether all three γ-secretase components occurred 
uniformly on BCG, APCs were infected with gfpBCG and stained for nicastrin, APH and 
presenilin using in situ immunofluorescence and followed by analysis of co-localization 
patterns. Figure 22 illustrates that all three components of γ-secretase were present and co-
localized with gfpBCG phagosomes, although, rather more intense staining was obtained 
with nicastrin. Western blot profiles confirmed that the three components of γ-secretase 
were present on BCG phagosomes and they could be specifically knocked-down using 
siRNA (Figure 23). In addition, BCG phagosomes purified from macrophages using sucrose 
gradients had enzymatically active γ-secretase, since they cleaved the amyloid precursor 
protein into an 87 kDa product (Figure 24).  
 
Membrane localization of nicastrin: Phagosomes intensely stained with antibody against 
nicastrin with very little cytosolic localization (Figure 22). To further confirm its presence 
on phagosomes, macrophages were infected with BCG and membrane or cytosol fractions 
were performed using digitonin extraction of cytosol and triton-X solubilized, cytosol free 
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membranes as described earlier (METHODS 5-11). Nicastrin was exclusively localized to 
membrane fraction in the presence or absence of L685,458  (Figure 25)  
 
γ-secretase components process phagosome derived proteins and thus affect antigen 
production: Since the proteolytic activity of γ-secretase was known and it was enriched on 
inert latex bead phagosomes, it was proposed that it may be involved in recycling and 
remodeling phagosome proteins.  Interestingly, mycobacteria like BCG vaccine and wild 
type Mtb secrete Ag85B that accumulates within the phagosomes (115,116). Ag85B has a 
major T cell epitope and is a powerful immunogen for mice and humans. This epitope is 
recognized by a T cell hybridoma, which in turn secretes IL-2 upon MHC-II dependent 
priming (48,64).  We therefore hypothesized that, mycobacterial phagosome derived Ag85B 
could be accessed and cleaved by γ-secretase components. Since a specific chemical 
inhibitor for γ-secretase (L685,458) is available and has been previously used to block 
nicastrin activity, we initially tested the effect of L685,458 on antigen presentation by 
macrophages and DCs infected with the BCG vaccine.  Figure 26 shows that L685,458 had a 
strong inhibitory effect on antigen presentation by both macrophages and DCs. As expected, 
a positive control of pepstatin, which is an inhibitor of cathepsin proteases, also inhibited 
antigen presentation. Finally, L685,458 showed a dose- dependent effect on antigen 
presentation by DCs infected with BCG (Figure 27). 
 
Phagosomes themselves present Ag85B assembled into MHC-II: It has been established 
that Mtb phagosomes themselves assemble Ag85B into MHC-II and present to BB7 T cells 
(48,64).  We speculated that L685,485 may have non-specific effects on antigen 
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presentation, including surface expression of MHC-II by macrophages. To rule out such non 
specific effects, BCG phagosomes were purified from macrophages using sucrose gradients, 
diluted and incubated directly with BB7 T cells. Figure 28 shows that intact BCG 
phagosomes treated with L658,485 showed inhibition of antigen presentation from BCG 
phagosomes compared to those from untreated and naïve macrophages.    
 
siRNA blockade of γ-secretase affects antigen production in macrophages and DCs: 
Nicastrin and presenilin have been reported to possess protease activity on their own (117-
121). To further define whether the three components of γ-secretase are involved in the 
generation of Ag85B peptide epitope through proteolysis, siRNA knockdown experiments 
were carried out. APCs were treated or untreated with siRNA against nicastrin, APH and 
presenilin followed by BCG or Mtb H37Rv infection and antigen presentation. Table-III 
shows the sequences of siRNA probes, which had a mix of at least two or three different 
siRNAs, which ensured robust and specific knock-down (Figure 23). Figure 29a (BCG) and 
Figure 29b (M.tuberculosis) show that siRNA knock-down of nicastrin , presenilin  and 
APH components of γ-secretase affected antigen presentation by APCs infected with BCG 
and to a significant extent with Mtb. Control scrambled siRNA had no significant effect on 
antigen presentation.    
 
L685,458 treatment of DCs affects subsequent in vivo immunogenicity : We have 
previously demonstrated that DCs infected with BCG vaccine can be used to elicit immune 
responses in mice following vaccination, which are protective against subsequent challenge 
with virulent tuberculosis (122).  This provided a model to examine the immunogenicity of 
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DCs infected with BCG. To obtain further evidence that γ-secretase may play a role during 
in vivo immunogenicity, DCs were treated or not with L685458, infected with BCG and 
injected to mice.  Viability of the DCs was >90% as evaluated by LDH release assays.  Two 
weeks later, splenic T cells were assayed for Ag85B specific responses of T cells secreting 
IFNγ using flow cytometric analysis of T cells harvested from spleens and ELISPOT 
analysis for Ag85B reactive T cells.  Figure 30 illustrates that, DCs infected with BCG 
elicited markedly better IFNγ+ CD4+ T cell response in mouse spleens compared to L685458 
treated DCs with BCG.  Similarly, ELISPOT analysis of corresponding spleens showed that 
they contained a higher proportion of Ag85B specific CD4+ T cells (Figure 30). These data 
strongly suggest that γ-secretase is likely to play a significant role in generating a peptide 
epitope from phagosome-associated Ag85B, and thus mediate immune recognition of 
mycobacteria, that are otherwise sequestered within macrophages and DCs.   
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Figure-22: BCG phagosomes within macrophages co-localize with γ-secretase 
components.  C57BL/6 mice derived primary macrophages were infected with gfpBCG 
and stained separately with antibodies to nicastrin, APH, presenilin or isotype control 
followed by Texas-red conjugates. Phagosomes co-localizing with γ-secretase components 
were scored using laser deconvolution microscopy and plotted. Panels show the three 
color panels for nicastrin and merged images for APH and presenilin. Isotype did not stain 
phagosomes and gfpBCG in dendritic cells showed a similar pattern (not shown). Bar 
graph represents percent co-localizing gfpBCG enumerated in 100 macrophages of 
triplicate chambers per experiment (n=3 experiments ± SD). 
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Figure-23 (left): siRNA mediated down regulation of phagosome associated 
proteins in macrophages and DCs. Macrophages and DCs were treated with siRNA vs. 
nicastrin, APH or presenilin and then infected with BCG organisms. After 24 hrs, 
phagosomes were purified and tested in western blot against antibodies against the 
proteins.  Blot profile shows down-regulation of proteins after siRNA treatment. 
Figure-24 (right): BCG phagosomes were purified from macrophages on sucrose 
gradients and analyzed for ability to cleave the amyloid precursor protein (APP). 
Macrophages were washed and infected with BCG. They were mixed for 4 hours and left 
overnight.  Cells were then scraped and BCG phagosomes isolated using sucrose 
gradients. Phagosomes were collected and incubated in PBS containing 5 mm EDTA and 
0.5 mm 1, 10-phenanthroline for 2 hours. Supernatants were analyzed using western blot 
and the 87 kDa APP band was detected using an antibody to APP (90 kDa marker).  
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Figure-25: Nicastrin is a membrane associated protease. Untreated or L685,458 
treated macrophages were infected with BCG vaccine strain and 24 hrs later, membrane 
and cytosol fractions were purified. After protein determination, equal amounts were 
loaded onto SDS-gels, electroblotted and analyzed for nicastrin using an antibody. 
Nicastrin is localized only to membrane fractions.  
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Figure-26: APCs infected with BCG vaccine present mycobacterial Antigen-85B to T 
cells and the process is inhibited by the γ-secretase inhibitor, L-685458. The 
primary APCs from C57BL/6 mouse bone marrow were treated or not with varying doses 
of γ-secretase inhibitor L-685485, followed by infection with BCG and antigen 
presentation to BB7 T cell hybridoma. L-685485 and positive control, Cathepsin inhibitor 
pepstatin, both inhibit antigen presentation.  
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Figure-27: L685458 shows a dose-dependent inhibition of antigen presentation in 
dendritic cells.  Primary DCs from C57BL/6 mouse bone marrow were treated or not 
with varying doses of γ-secretase inhibitor L-685485 and Ag85B presentation was 
evaluated (one of two similar experiments shown).  
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Table IIII: Compilation of experiments performed utilizing L685,458 
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Figure-28: Purified BCG-phagosomes from macrophages present mycobacterial 
Antigen-85B to T cells and the process is inhibited by the γ-secretase inhibitor, L-
685,458. The primary APCs from C57BL/6 mouse bone marrow were treated or not 
(naïve) with 100 µM of γ-secretase inhibitor L-685,485, followed by purification of BCG 
phagosomes which were diluted, and incubated with BB7 T cells (pahosome:T cell ratio). 
IL-2 released from T cells was measured.  L-685,485 inhibits antigen presentation from 
BCG phagosomes to BB7 T cell hybridoma (one of two similar experiments shown). 
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Table-V:  siRNA sequences of probes and controls used to knock-down the components of γ-
secretase 
 
  
Santa Cruz APH siRNA is a pool of 2 different siRNA 
duplexes: 
 
• Sense: GGUUUGGCGUUGUCCAUUUtt 
• Antisense: AAAUGGACAACGCCAAACCtt 
 
• Sense: CAUCAUUAGUGGUGUAACUtt 
• Antisense: AGUUACACCACUAAUGAUGtt 
 
Invitrogen APH siRNA has a sequence of  
 
• Sense: AAAGCGGAACACCUCCUGUAGAAG 
 
Santa Cruz Nicastrin siRNA (m) is a pool of 3 different siRNA 
duplexes: 
 
• Sense: CGUAGUGGAGAAAGAAGAAtt 
• Antisense: UUCUUCUUUCUCCACUACGtt 
 
• Sense: CAACGGCUUGGCUUAUGAAtt 
• Antisense: UUCAUAAGCCAAGCCGUUGtt 
 
• Sense: GUGACCCCUUAUCUGACUAtt 
• Antisense: UAGUCAGAUAAGGGGUCACtt 
 
Invitrogen Nicastrin siRNA has a sequence of  
 
• Sense: UAUCAUAGACCAUCCGUGAGCUGCC 
 
Santa Cruz Presenilin siRNA (m) is a pool of 3 different siRNA 
duplexes: 
 
• Sense: GAGUGGAGCUAGAGAUAGAtt 
• Antisense: UCUAUCUCUAGCUCCACUCtt 
 
• Sense: CCAGAAUGACAGCCAAGAAtt 
• Antisense: UUCUUGGCUGUCAUUCUGGtt 
 
• Sense: CUACGUGUCCAACCAAUCAtt 
• Antisense: UGAUUGGUUGGACACGUAGtt 
 
Invitrogen Presenilin siRNA has a sequence of  
 
• Sense: UAGAAACGCACAGACUUGAUAGUGG 
 
The sequence of Control siRNA-A is: 
 
• Sense: UUCUCCGAACGUGUCACGUTT 
• Antisense: ACGUGACACGUUCGGAGAATT 
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Figure-29: siRNA blockade of the components of γ-secretase leads to inhibition of 
antigen presentation in APCs. APCs were treated or not with siRNA against γ-secretase 
components, followed by infection with either BCG (a: top panel) or Mycobacterium 
tuberculosis (b: bottom panel) and antigen presentation. siRNA knock down of presenilin 
and nicastrin significantly affects antigen presentation (p values, student t test;  
comparison between siRNA control vs. siRNA knock downs). 
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Table-VI: Compilation of siRNA knockdown experiments performed 
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Figure-30: γ-secretase inhibitor L
cells in vivo.  C57BL/6 mouse bone marrow derived DCs were left u
a low (1 µg per 106 DCs) or high dose (10 µg per 10
685,458 followed by infection with BCG. Washed DCs we
weeks later, spleen T cells were analyzed for IFN
Ag85B specific T cells using ELISPOT (panel b). 
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CHAPTER 4 
 
 
 
DISCUSSION AND CONCLUSIONS 
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Tuberculosis is a leading cause of death due to infections in mankind. A vaccine is most 
useful to prevent tuberculosis and BCG vaccine has been used for nearly a century, with 
partial success. Development of a more successful vaccine is a priority for WHO and 
various health institutions around the world.  In this study, we sought to understand the 
mechanisms through which antigenic peptides are produced from BCG, which are 
eventually sorted and presented to the CD4+ T cells through an MHC-II dependent pathway. 
We initiated our research looking into the immune-evasive mechanisms of M.tuberculosis, 
which is very closely related to BCG vaccine. 
 
The seminal observation by Armstrong and Hart that wild type M.tuberculosis sequesters in 
immature phagosomes of macrophages laid the foundation for the pathogenesis of 
tuberculosis (123-125). By localizing in immature endosomes and not fusing with 
lysosomes, wild type Mtb is able to avoid the proteases, lipases and nucleases within the 
hostile environment of lysosomes. Since lysosomal degradation is the source of peptides that 
are then sorted into MIIC compartments for MHC-II loading, it seems obvious that the 
virulent Mtb has an immune evasion strategy. Interestingly, even the attenuated BCG 
vaccine was reported to be sequestered from human CD4+ T cells, although the molecular 
mechanisms remained unclear (126). A series of studies following this observation showed 
that enabling BCG or its antigens to leak into cytosol enhanced its immunogenicity, over-
expression of antigens within BCG boosted its efficacy and finally, rapamycin inhibition of 
the mTOR pathway induces BCG to localize into autophago-lysosomes and increases the 
vaccine efficacy (122,127-130). These studies have markedly improved BCG vaccine 
through genetic or immunologic manipulation. However, the mechanism through which the 
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mammalian immune system recognizes sequestered Mtb pathogen or BCG vaccine within 
APCs still remains unclear. Such mechanisms are clearly important to devise effective 
immunization strategies against tuberculosis.   
 
A significant mechanism through which immune recognition can occur could be through 
processing of antigens secreted from Mtb and BCG. Mtb secretes a number of antigens like 
Ag85 complex (A, B and C), ESAT-6, CFP-10 and TB10.4 among others.  BCG also 
secretes Ag85 complex and TB10.4, but is deficient in ESAT-6 and CFP-10 (131-134).  
Since secreted proteins are major immune-dominant antigens in mice and humans, it has 
been speculated that under natural conditions of infection or vaccination, the immune system 
mostly recognizes secreted protein antigens through either MHC-I or MHC-II pathways 
(52,53). This is evident from the overwhelming T cell and antibody responses to secreted 
antigens of Mtb and BCG vaccine in animal models and humans.  
 
The MHC-II dependent CD4+ T cells appear to be more active against active infection since, 
HIV-1 infected humans with CD4+ T cell depletion rapidly succumb to tuberculosis. 
However, MHC-I dependent CD8+ T cells also appear important, although, there seem to be 
impediments for proteasome-mediated processing of secreted antigens for CD8+ responses. 
Thus, despite secreting Ag85 complex proteins, BCG is a poor inducer of CD8+ responses 
and expression of pore-forming listeriolysin toxin was found to enhance CD8+ responses in 
mice (135). Antigens 85A-B-C and pstS are major immunogenic proteins of BCG vaccine, 
and yet, only a limited number of CD8+ epitopes have been mapped using tetramers in mice. 
In contrast, most secreted antigens are well known to trigger CD4+ T cells responses, 
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although, the sorting of secreted antigens, located in the cytosol into MHC-II dependent 
pathway remains unclear. The processing of secreted antigens of BCG vaccine within 
phagosomes was therefore a major focus of this study. 
 
We described recently that intact BCG vaccine and its antigens could be routed to lysosome 
like compartments through induction of autophagy in macrophages and DCs (122).  
However, Ramachandra et al. described that mycobacterial phagosomes by themselves 
could assemble peptides in situ into MHC-II complexes, which are then exported to plasma 
membranes for presentation to CD4+ T cells (63,64).  In subsequent studies, we used an in 
vitro Ag85B antigen presentation assay to identify that Cathepsin-D was a major protease 
that cleaved Ag85B to produce a CD4+ T cell epitope (36). Though BCG produced limited 
amounts of Ag85B epitope to be presented to BB7 T cells, it was interesting because, the pH 
of BCG phagosomes was near neutral, and the purified BCG phagosomes contained reduced 
amounts of active 30 kDa Cat-D required to produce Ag85B epitope. Keeping in mind that 
in vivo, phagosome environment could be variable, we asked a question, whether Ag85B 
epitope production in phagosomes was determined solely by pH dependent activation of 
Cat-D and similar enzymes  or whether other proteolytic processes were present.  
 
Studies described here show that both vATPase and phagocyte oxidase (phox, NADPH 
oxidase) play a major role in the regulation of lumen pH, but the BCG vaccine derived SOD 
seems to negate the effects of vATPase and phox by maintaining a neutral pH. Thus, 
knocking down the expression of  SOD  through  genetic manipulations led to a more 
immunogenic phenotype for BCG vaccine. This vaccine is currently under clinical trials and 
75 
 
it is a possible candidate to replace BCG wild type vaccine. By investigating the pH 
regulation processes therefore, we were able to find a novel molecular basis to improve the 
BCG vaccine. Even after blockade of vATPase and phox, we observed that macrophages 
still presented antigen to T cells. Thus, we speculated that alternate mechanisms or proteases 
may be present within the phagosomes. 
 
In an attempt to further characterize proteases associated with the phagosome, we then 
performed a proteomic analysis of BCG and Mtb phagosomes and identified that nicastrin 
was enriched on phagosomes (92-94). The enrichment of nicastrin on mycobacterial 
phagosomes was initially identified during a proteomics that was confirmed by others 
(94,136). Data reported in this study suggest that, nicastrin is associated with a proteolytic 
cleavage of Ag85B to produce an immune signal. Our observations using proteomic analysis 
are novel and thought provoking in several directions. First, we had documented earlier that 
the phagosome pH is near neutral that prevents the generation of sufficient levels of active 
proteases within the phagosome lumen (36). Being associated with the phagosome 
membrane, nicastrin may not be affected by the intracellular environment of the phagosome 
and thus may aid in proteolysis, either at the membrane interface or outside the membrane. 
We noted that purified BCG phagosomes themselves were capable of priming BB7 T cells 
in vitro and this was affected by L685458, an inhibitor of γ-secretase. The assembly of 
nicastrin alone or as a part of γ-secretase on the phagosome membrane may also help to 
perform a physiological function involved in endosome recycling, as proposed by Jutras et 
al. (99).  Nicastrin or γ-Secretase may therefore fortuitously cleave the mycobacterial 
proteins helping the immune system to recognize the intraphagosomal mycobacteria. Third, 
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γ-secretase may potentially produce shorter peptide fragments, and downstream events may 
channel them towards an alternate CD8+ pathway. We therefore propose that γ-secretase and 
its components perform an unintended proteolytic function at the phagosome level and this 
may benefit the host during infections.  
 
It is tempting to hypothesize that we may be able to exploit the proteolysis function of γ-
secretase. For example, we can clone and express an immunogenic protein into CD44, a 
known substrate of γ-secretase and express it within BCG as a secreted protein. Then, one 
can expect γ-secretase to cleave CD44 as well as associated antigen and produce peptides 
that could conceivably find their way into antigen presentation. Furthermore, we can use an 
SOD mutant to express CD44 that will probably facilitate a lumen with acidic environment, 
and aid proteolysis in situ. Future studies can focus on these issues to strengthen the BCG 
vaccine.   
 
To conclude, a comprehensive examination of events occurring within the BCG vaccine 
phagosomes has helped to unravel some novel mechanisms that seem to determine the 
efficacy of the BCG vaccine. Our studies have highlighted that the mycobacterial 
phagosomes contain in excess of 400 proteins indicating the complexity of the phagosome 
and the daunting task of a functional characterization. Interestingly, this study illustrates the 
use of a system biology approach to dissect the function of a phagosome-associated protein. 
We anticipate that a similar systems-biology approach will enable analysis of other novel 
proteins associated with the phagosomes and help in understanding pathogenesis and 
vaccine development.    
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Figure-31: Summary of findings from this study. Because the BCG vaccine does not fuse 
with lysosomes, much of the antigen-85B derived epitope is produced within the 
phagosomes. The phagosomes have two pumps, vTPAse and phagocyte oxidase (phox) that 
work in opposing directions, reducing pH and increasing pH, respectively. The acidic pH 
facilitates the generation of 30 kDa Cat-D that can cleave and produce Ag85B epitope, 
which is then presented to the T cells. The BCG vaccine secretes superoxide dismutase that, 
in turn, raises pH of the lumen. This leads to reduced levels of antigen production in a 
neutral phagosome. In addition to, the pH regulating pumps, a third membrane associated 
protease, γ secretase also seems capable of cleaving Ag85B. Thus, the BCG vaccine 
phagosome is a critical determinant of immune responses originating from macrophages and 
DCs.  
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Chapter 5  
 
 
 
Materials and Methods 
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5-1 PRIMARY MACROPHAGES, DCS, CEL LINES, AND BCG STRAINS 
Bone marrow from C57BL/6 mice (M/F)(4-8 weeks) (Jackson research Labs, USA) was 
obtained by flushing both the femur and tibia.  The bone marrow pooled from 2 mice at a 
time was centrifuged for five minutes at one thousand rotations per minute.  The bone 
marrows were washed two times in ACK lysing buffer (Fisher BW10-548E), followed by 
one milliliter (ml) ,of phosphate buffered saline (PBS), passed through a 36-gauge needle 
and suspended in Iscove’s modified Dulbecco’s medium (IMDM) with ten percent fetal 
bovine serum (FBS), 20 ng per milliliter granulocyte macrophage colony stimulating factor 
(GM-CSF), and antibiotics, penicillin and gentamicin. The cells were then plated into six 
well plates and incubated at 37oC, 5% CO2 for one week, while spiking the wells with two 
milliliters of fresh media, every two days.  After seven days, the wells are flushed and the 
cells from several plates are transferred to a 50ml screw cap tube. The cells are pelleted and 
resuspended in MACS buffer, PBS containing 0.5% FBS, at a volume of 400µl per 108 cells.  
CD11c microbeads (Miltenyi 130-052-001) were then added to the cells, 100µl per 108 cells.  
The cells were incubated at 4oC for fifteen minutes, washed once in 1ml of MACS buffer 
and resuspended into 500 µl MACS buffer.  During this time, the Miltenyi separation 
columns (Miltenyi 130-042-201) were prepared by rinsing once with 500 µl MACS buffer, 
one column per 108 cells and placed onto magnetic holders.  The cells are added to the 
columns and the flow through is collected.  The macrophages will flow through since they 
do not have CD11c on their surface, thereby not binding the microbeads.  The columns are 
washed three times with 500 µl MACS buffer and then removed from the magnetic holders. 
One milliliter dissociation buffer is then plunged through the column, thereby washing the 
dendritic cells off the column. Wash off was repeated once. The flow-through macrophages 
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were then run through another column repeating the procedure.  The cells (DCs and 
macrophages) are counted and plated into twenty-four well plates with 106 cells per well in 
IMDM supplemented with 10% FBS and GM-CSF and allowed to differentiate for 4-7 days. 
Medium was replaced with GM-CSF free medium and cells were used for various assays 
(36). BMA A1, derived from C57Bl/6 mice, macrophage cell line used for obtaining 
phagosomes and was a kind gift from Dr. Kenneth L. Rock (UMASS, Cambridge, USA). 
 
BCG Pasteur was from ATCC collection, BCG Tice strain and the mutants were donated 
from Dr. D. Kernodle from Vanderbilt university and gfpBCG was a gift from Dr. 
Dhandayuthapani, UTHSC-SA. 
       
5-2 ANTIGEN PRESENTATION ASSAY 
Macrophages or dendritic cells in 24 well plates were infected with BCG at a multiplicity of 
infection (MOI) of 5:1.  The cells were placed on a shaker at 37oC, 5%CO2 for four hours or 
18 hrs as per experiment.  Monolayers were then washed with fresh medium three times to 
remove non-phagocytosed bacteria, and overlaid with 250µl of BB7 T cells, at a ratio of 
1:20. These cells specifically recognize MHC class II loaded with a peptide from the 
mycobacterial antigen 85B (aa 241-256: VANNTRLWVYCGNGTP). The plates were 
either  incubated for 4-24 hrs depending upon the experiment. The supernatant was collected 
and tested for IL-2 using sandwich ELISA kit from Biolegend Inc (USA) (36). 
 
5-3 PROTEIN ASSAY 
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Protein assays for phagosomes were performed utilizing the BCA Protein Assay Kit 
(Thermo Scientific Pierce-23225).  The protocol followed was as described in the Pierce 
BCA Protein Assay Kit.  Equal amounts of proteins were loaded per lane of SDS gels in all 
experiments.   
 
5-4 WESTERN BLOTS 
Western blot analysis was performed utilizing Bio-Rad pre-cast Criterion gels and gel 
system.  Controls used in all experiments were Pierce Blue Ranger pre-stained markers as 
well as the Cruz marker (Santa Cruz Biotechnology, CA).  SDS gels were run and 
transferred to Bio-Rad Immuno-Blot Polyvinylidene Fluoride (PVDF) membranes.  All 
primary antibodies were incubated overnight and secondary antibodies for 90 minutes(36).  
ECL kit was used to develop the blots. 
 
5-5 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA) 
Following the Biolegend protocol, ninety-six well ELISA plates were coated with 100µl per 
well of IL-2 capture antibody (Biolegend 431003 IL-2 Kit) and incubated overnight at 4oC.  
The plates were then blocked for two hours with 200 µl PBS containing 1% albumin per 
well.  After blocking the plates, 100 µl of sample, or IL-2 standard was added and the plates 
were then incubated overnight at 4oC.  The ELISA plates were washed with PBS containing 
0.05% Tween-20 three times.  100µl detection antibody per well was added to each well and 
the plates were incubated at room temperature for two hours.  The plates were washed again 
and 100µl of avidin-HRP per well was added and incubated for thirty minutes.  The plates 
were washed for the final time and 100µl Sure Blue TMB 1-component per well peroxidase 
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substrate (KPL 50-00-01) was added and incubated for fifteen minutes.   50µl Stop solution, 
2N H2SO4, was added to each well and the plates were read at 450nm.  A standard curve 
was calculated using the IL-2 standards loaded on the plates, and the IL-2 content of 
samples was determined.  
 
5-6 IMMUNOFLUORESCENT STAINING   
Dendritic Cells or macrophages were plated onto 8-chamber glass slides (BD 354118).  The 
slides were incubated overnight at 37oC, 5%CO2 in activator-free medium or activators, such 
as Gm-CSF, for 4 or 24 hrs. Cells were infected with gfpBCG and placed on a shaker at 
37oC, 5%CO2 for four hours, removed from the shaker and incubated for 4-8 or eighteen 
hours.  Slides were washed with PBS three times and 200µl of 2.7% paraformaldehyde was 
added to each chamber for fifteen minutes.  200µl of .01mg/ml digitonin in PBS was added 
to each well and incubated for eight minutes.  The paraformaldehyde was aspirated and cells 
were then incubated in 200µl perm buffer, containing 0.1% saponin and 0.05% tween-20 in 
PBS, and incubated for thirty minutes.  Blocking buffer consisting of 0.1% glycine and 5% 
heat inactivated mouse serum in PBS was added and slides were incubated for 30 minutes.  
Primary antibody was added to the slides and they were incubated overnight at 4oC.  Slides 
were then washed thrice with PBS containing 0.05% tween and Texas Red secondary 
(Jackson Immunoresearch Chemicals, USA) was added to each well and slides were 
incubated for three hours.  Isotype specific antibodies were used in the place of primary 
antibody as a control in all steps of our experiments. Slides were then washed and rinsed 
once with cold methanol.  Slides were then scoped and analyzed using a Nikon microscope 
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with Metaview software.  Co-localization was confirmed using laser confocal microscopy 
when needed (36).   
 
5-7 PHAGOSOME FRACTIONATION  
The method described by Ullrich et al. to purify mycobacterial phagosomes was used 
without modifications [135].  Antigen presenting cells (BMA.A1 cell line, CyDC cell line or 
primary cells) were infected at an MOI of 5:1 with BCG, or other mycobacteria, gently 
mixed for 4 hours at 37oC, 5% CO2 and then incubated for eighteen hours.  Cells were then 
scraped and samples were pooled from multiple flasks.  Cells were washed three times with 
PBS and resuspended in an anti-protease mix consisting of 1 µg/mL leupeptin, 1 µg/mL 
pepstatin and 1 mM phenylmethyl sulfonylfluoride.  Cells were then transferred to a glass 
cell grinder and ground prior to being passed through a syringe with a 27½ gauge needle.  
Cells were then layered on a gradient composed of 4 mL 50% sucrose and 2 mL of 12% 
sucrose and centrifuged for 90 minutes at 4oC at 2000 rpm.  The interface, composed of 
phagosomes, was collected after removing the upper 12% sucrose layer (post nuclear 
supernatant).  The phagosomes were pelleted at 12000 rpm for 5 min and the supernatant 
was discarded.  500 µL of PFB (0.5 mm EDTA, 0.5 mM EGTA, 0.05% gelatin and 20 mM 
hepes brought to a pH of 7.0) was added and phagosomes were overlaid on 2 ml of 10% 
Ficoll 70,000 in 5% sucrose, centrifuged at 2000 rpm for 30 min and the interface was 
collected. This second step was repeated once more to yield > 95% pure phagosomes as 
judged by electron microscopy (137).  
 
5-8 PROTEOMIC ANALYSIS (method reproduced from Li et al, IJCLM(92,93)) 
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Phagosomes were fractionated as noted previously, Methods, prior to further analysis. 
Samples of 100 µg phagosomes containing BCG, Mtb H37Rv or ∆fbpA were fractionated 
into five SDS/PAGE gel fractions. Peptide extracts from each fraction were purified before 
analysis.  Analysis was performed with a nanoLC/LTQ-FTMS system at the Proteomics and 
Informatics Facilities Services in the Research Resources Center at University of Illinois at 
Chicago (PISF-RRC-UIC), which is supported by the Searle Funds at the Chicago 
Community Trust. Each extract was injected once and a total of 15 LC/MS injections were 
performed for the three phagosome samples. With the Sorcerer server (Sage-N Research, 
Inc.; Milpitas, CA) hosted at the PISF-RRC-UIC, the raw data files were compared to a 
composite database containing the protein databases of mouse, H37Rv, BCG, and their 
reversed decoy databases.  The raw data files were then converted to mzXML files using the 
Trans-Proteomic Pipeline software. The mzXML files were searched against the composite 
database as well. For reference, the peptide mass tolerance was set at 15 ppm with 
methionine oxidation as a differential modification.  Up to 2 missed cleavages and an 
isotope check using a mass shift of 1.003 amu were allowed with only MS/MS 
identifications with peptide probability above 0.5 for quantitation being accepted for 
publication.   
5-9 siRNA KNOCKDOWN OF PRIMARY CELLS 
A specific approach to inhibit γ secretase component expression is the use of siRNA against 
APH, nicastrin or presenilin.  This procedure from Santa Cruz Biotechnology involves 
transfecting macrophages or dendritic cells with long double stranded RNA, which upon 
uptake, enter the RNA interference pathway.  The RNA is degraded into 19-21 nucleotide 
fragments by an RNAase III enzyme called dicer, and subsequently this binds to the 
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complimentary mRNA sequence.  The coupled mRNA is then cleaved prior to translation, 
thus inhibiting production of the targeted protein.  Primary cells are transfected utilizing 
Santa Cruz’s Transfection Reagent and incubated for 30 hours. siRNA-transfected as well as 
naїve cells were infected with mycobacterial strains for 4 hrs and washed. At this stage, 
replicate wells of cells were lysed to determine protein content by western blot. Other wells 
were washed and incubated in medium for 24 h and then overlaid with BB7 T cells. IL-2 
was then estimated at several time points of incubation.  The controls used are scrambled 
sequences of siRNA. 
 
5-10 pH DETERMINATION  
Macrophages were plated in 8-well coverglass bottom chambers (Lab-Tek, Naperville, IL). 
After 24 h when the cells were 30–50% confluent, they were incubated in 1 mg/ml of the pH 
indicator LysoSensor Yellow/Blue dextran (Molecular Probes, Eugene, OR) for 12 h  and 
then washed with cold PBS. Macrophages were acidified using 60 min incubation with 
nigericin if needed. LysoSensor is an UV-excited fluorophore with emission maxima at 390, 
450 and 530 nm that are proportional to pH. This dextran-conjugated indicator is taken up 
by vesicles that are part of the endocytic pathway and are comprised of endosomes and 
lysosomes. Higher 530/450 nm ratios correlate with a lower pH. The labeled cells were 
observed with a fluorescent microscope (Nikon microscope with a Metamorph image 
analysis software), using excitation at 360 nm and an emission filter at 450 nm and a long 
pass emission filter at 515 nm. With the dextran-labeled LysoSensor Yellow/Blue dye, the 
ratio of 530/450 nm emission was calculated for endocytic vesicles by using the MetaMorph 
Image (or Metaview) processing system (Version 4.5r5, Universal Imaging Corp., PA) and 
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averaged for each image(138). The 530/450 nm ratio was calculated on a minimum of 100 
intracellular phagosomes in each of the four images analyzed per experiment and each 
experiment was repeated three times (arbitrarily we can score the phagosomes as green and 
blue and express their ratio to reflect the pH). 
 
5-11 FRACTIONATION OF CYTOSOL AND MEMBRANE FRACTIONS FROM  
        PRIMARY CELLS 
Primary macrophages or dendritic cells are plated into 6-well plates at a count of 2x106 cells 
per well in IMDM with 10% FBS.  The APCs are incubated 24 hours prior to treatment or 
infection.  If a treatment is performed on the APCs, they are treated for 24 hours prior to 
infection, which is then allowed to proceed for an additional 24 hours.  The cells were then 
washed thrice with 1 ml PBS and then incubated on ice with 300 µl digitonin in a sucrose 
buffer(139,140).  The plates are incubated for 10 minutes and the buffer is then collected 
and pooled.  The samples are then concentrated using Centricon centrifugal ultrafiltration 
vials until a final volume of 100 µl is obtained.  This sample is termed the cytosolic fraction.  
The wells of the plates are then scraped using a cell scraper, and rinsed with 1ml PBS 
combining wells of the same sample.  The samples are then centrifuged at 12000 rpm for 
five minutes, and washed three times with PBS containing 10% Triton-X and then 
resuspended in PBS.  This portion of the sample is now termed the membrane fraction and 
stored after protein determination.     
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